The Democratic Republic of Congo (DRC) is
facing its tenth Ebolavirus (EVD) outbreak since August 2018. Ebola virus
disease is a rare but deadly disease in people and non-human primates. The
current Ebolavirus disease (EVD) outbreak in the provinces of North Kivu and
Ituri is the tenth outbreak affecting the Democratic Republic of Congo (DRC);
the first outbreak occurring in a war context, and the second most deadly
Ebolavirus outbreak on record following the 2014 outbreak in West Africa. The
primary aim of the study is to give an update on the situation of recurrent
Ebola virus disease in the Democratic Republic of Congo and provide insight
into the challenges associated with managing and controlling the disease. The
DRC government’s response consisted of applying a package of interventions
including detection and rapid isolation of cases, contact tracing, population
mapping, and identification of high-risk areas to inform a coordinated effort.
The coordinated effort was to screen, ring vaccinate, and conduct laboratory
diagnoses using GeneXpert (Cepheid) polymerase chain reaction. The effort also
included ensuring safe and dignified burials and promoting risk communication,
community engagement, and social mobilization. Following the adoption of the
“Monitored Emergency Use of Unregistered Products Protocol,” a randomized
controlled trial of four investigational treatments (mAb114, ZMapp, and REGN-
EB3 and Remdesivir) was carried out with all consenting patients with
laboratory-confirmed EVD. REGN-EB3 and mAb114 showed promise as treatments for
EVD. In addition, one investigational vaccine (rVSV-ZEBOV-GP) was used first,
followed by a second prophylactic vaccine (Ad26.ZEBOV/MVA-BN-Filo) to reinforce
the prevention. Although the provision of clinical supportive care remains the
cornerstone of EVD outbreak management, the DRC response faced daunting
challenges including general insecurity, violence and community resistance,
appalling poverty, and entrenched distrust of authority. Ebolavirus remains a
public health threat. Fully curative treatment is unlikely to be a game-changer
given the settings of transmission, zoonotic nature, limits of the
effectiveness of any therapeutic intervention, and timing of presentation.
Author(s)
Details:-
Joseph
Inungu
College of Health Professions, Central Michigan
University, Michigan, United States.
Kechi
Iheduru-Anderson
Central Michigan University, Michigan, United
States.
Ossam
J. Odio
Department of Internal Medicine, Medical School
Hospital, University of Kinshasa, Kinshasa, Democratic Republic of Congo.
Please see the link here: https://doi.org/10.9734/bpi/rudhr/v6/8299E
No comments:
Post a Comment